regulatory qualification for the ebmt patient registry for car t-cell therapy
Published 5 years ago • 65 plays • Length 2:46Download video MP4
Download video MP3
Similar videos
-
2:22
the regulatory process for car-t in europe: ebmt registry & gocart
-
1:51
regulatory and commercialization challenges with car t-cell therapy
-
6:51
role of the ebmt registry on reporting car t-cell outcomes
-
1:53
the detection and management of mnts following bcma-directed car-t therapy
-
1:36
education initiatives for car t-cell therapy
-
1:26
ebmt guidelines car-t education & guidelines for nurses
-
2:05
the cost-effectiveness of car t-cell therapy
-
0:58
improving the long-term safety of cll treatment
-
1:07
key advancements in the treatment of bpdcn from ebmt 2024
-
2:26
the future directions of ebmt: introduction of cellular and gene therapy
-
1:39
the role of myeloid cells in car-t cell therapy
-
1:53
phe885, a t-charge manufactured bcma-directed car-t therapy in r/r myeloma
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all
-
2:43
resistance to car t-cell therapy
-
1:06
how will novel agents & car-t cells affect the future treatment landscape in b-all?
-
2:12
the regulation of personalized medicine trials
-
2:20
ebmt diagnostic criteria for tma post-allosct and the role of complement activation
-
1:13
the future of the ebmt patient advocacy track
-
1:42
the future of car-t and bispecifics in myeloma: successful integration into earlier lines